Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lisa Rojkjaer Insider Profile
4 Followers
Lisa Rojkjaer, CMO at Viracta Therapeutics, holds 19.72K shares in Rigel (Ticker: RIGL), holds 48.09K shares in Viracta Therapeutics (Ticker: VIRX).
Lisa Rojkjaer has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Lisa Rojkjaer holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Lisa Rojkjaer
Lisa Rojkjaer's Trading History
Viracta Therapeutics
Feb 28, 2023
CMO
Uninformative Buy
3.43K
$1.78K
Rigel
Jan 31, 2025
EVP, Chief Medical Officer
Uninformative Buy
―
$396.11K
List of latest transactions for each holding click on a transaction to see Lisa Rojkjaer's performance on stock
You May Also Like
Lisa Rojkjaer insider profile FAQ
What is the percentage of profitable transactions made by Lisa Rojkjaer?
The percentage of profitable transactions made by Lisa Rojkjaer is ―.
What is the average return per transaction made by Lisa Rojkjaer?
The average return per transaction made by Lisa Rojkjaer is ―.
What stocks does Lisa Rojkjaer hold?
Lisa Rojkjaer holds: VIRX, RIGL stocks.
What was Lisa Rojkjaer’s latest transaction?
Lisa Rojkjaer latest transaction was an Uninformative Buy of ―.
What was Lisa Rojkjaer's most profitable transaction?
Lisa Rojkjaer’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Lisa Rojkjaer's role in Viracta Therapeutics?
Lisa Rojkjaer's role in Viracta Therapeutics is CMO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.